Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System

Cellectis

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application PCT/EP2014/056534, filed Apr 1, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,584,352	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Term ends Apr 1, 2034 · High confidence	Cellectis	In force	Term ends Apr 1, 2034	Term ends Apr 1, 2034	High confidence
US 10,870,864	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Term ends Apr 1, 2034 · High confidence	Cellectis	In force	Term ends Apr 1, 2034	Term ends Apr 1, 2034	High confidence
US 11,365,430	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Term ends Apr 1, 2034 · High confidence	Cellectis	In force	Term ends Apr 1, 2034	Term ends Apr 1, 2034	High confidence
US 9,855,297	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Term ends Apr 11, 2034 · High confidence	Cellectis	In force	Term ends Apr 11, 2034	Term ends Apr 11, 2034	High confidence
US 9,890,393	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Term ends Apr 11, 2034 · High confidence	Cellectis	In force	Term ends Apr 11, 2034	Term ends Apr 11, 2034	High confidence
US 11,959,091	Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System Cellectis In force Ends no later than Jan 14, 2036 · Medium confidence	Cellectis	In force	Ends no later than Jan 14, 2036	Ends no later than Jan 14, 2036	Medium confidence

6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.